The Editorial on the Research Topic
Oxytocin: Control of Bone and Fat Mass and Metabolism
Osteoporosis and overweight/obesity constitute major worldwide public health burdens. Human life expectancy has increased continuously in industrialized countries. Aging is associated with immunosenescence, a decrease in hormonal secretion, lean mass, and bone mass, and an increase in fat accumulation. It has been reported that both obesity and osteoporosis are affected by genetic and environmental factors; bone remodeling and adiposity are both regulated through the hypothalamus and sympathetic nervous system (1–3). Furthermore, mesenchymal stem cell represents a common precursor for adipocytes and osteoblasts; adipose tissue and skeleton are known endocrine organs. Oxytocin (OT) belongs to the pituitary hormone family and regulates the function of peripheral target organs, including the mammary glands and smooth muscle of the uterus (4). Due to this property, it has commonly been used in other medical obstetrics without significant side effects (5). It also modulates a wide range of behaviors, such as social recognition, love, and fear (6–9). Of note, it has been established that OT pathway was involved in the physiology of bone remodeling by the analysis of OT and its cognate receptor knock-out mice (10). Furthermore, OTR-deficient mice exhibit disorders in several aspects of social behavior, bone defects, and develop late-onset obesity (10–14). Thus, OT emerges as a promising molecule in the treatment of osteoporosis and obesity as well as associated metabolic disorders such as type 2 diabetes.
The levels of OT decreased with age. The crosstalk between bone and energy metabolism has been clearly evidenced in the last years through the investigations on the role of leptin, osteocalcin, and other molecules. Several reports, published recently, show clearly that OT could play an important role in the control of bone and fat mass and their metabolism (15–21). In conclusion, there are growing evidences showing that administration of OT holds promise as a potential therapy for both osteoporosis and weight gain/obesity, and may represent the first therapy targeting these two diseases linked to aging and their associated pathologies such as diabetes and cardiovascular disorders.
In this research topic, we were able to assemble articles from prominent scientists in the field, which focused on different aspects of OT. It contains four reviews and two original research articles. The topic started with a mini review regarding the central role of OT and food intake (Klockars et al.) followed by an update on the relationship between fat and bone (Colaianni et al.), then a review on OT treatment in relation to leptin signaling (Altirriba et al.), analysis of OT treatment against diabetes and osteoporosis (Elabd et al.), and finally two research articles describing the sex-dependent effects of OT (Beranger et al.) and the importance of OT receptor in the control of thermoregulation (Kasahara et al.).
I would like to thank the contributors and the reviewers for their help in putting interesting manuscripts in this special research topic.
Author Contributions
The author confirms being the sole contributor of this work and approved it for publication.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
- 1.Greco EA, Lenzi A, Migliaccio S. The obesity of bone. Ther Adv Endocrinol Metab (2015) 6:273–86. 10.1177/2042018815611004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Misra M, Klibanski A. Anorexia nervosa, obesity and bone metabolism. Pediatr Endocrinol Rev (2013) 11:21–33. 10.1159/000443735 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kawai M, de Paula FJ, Rosen CJ. New insights into osteoporosis: the bone-fat connection. J Intern Med (2012) 272:317–29. 10.1111/j.1365-2796.2012.02564.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol (2014) 26:356–69. 10.1111/jne.12154 [DOI] [PubMed] [Google Scholar]
- 5.Smith JG, Merrill DC. Oxytocin for induction of labor. Clin Obstet Gynecol (2006) 49:594–608. 10.1097/00003081-200609000-00019 [DOI] [PubMed] [Google Scholar]
- 6.Neumann ID. Oxytocin: the neuropeptide of love reveals some of its secrets. Cell Metab (2007) 5:231–3. 10.1016/j.cmet.2007.03.008 [DOI] [PubMed] [Google Scholar]
- 7.Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci (2005) 25:11489–93. 10.1523/JNEUROSCI.3984-05.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature (2005) 435:673–6. 10.1038/nature03701 [DOI] [PubMed] [Google Scholar]
- 9.Onaka T, Takayanagi Y, Yoshida M. Roles of oxytocin neurones in the control of stress, energy metabolism, and social behaviour. J Neuroendocrinol (2012) 24:587–98. 10.1111/j.1365-2826.2012.02300.x [DOI] [PubMed] [Google Scholar]
- 10.Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A (2009) 106:7149–54. 10.1073/pnas.0901890106 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci U S A (1996) 93:11699–704. 10.1073/pnas.93.21.11699 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet (2000) 25:284–8. 10.1038/77040 [DOI] [PubMed] [Google Scholar]
- 13.Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A (2005) 102:16096–101. 10.1073/pnas.0505312102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport (2008) 19:951–5. 10.1097/WNR.0b013e3283021ca9 [DOI] [PubMed] [Google Scholar]
- 15.Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 6:e25565. 10.1371/journal.pone.0025565 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zhang G, Bai H, Zhang H, Dean C, Wu Q, Li J, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron (2011) 69:523–35. 10.1016/j.neuron.2010.12.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY) (2011) 3:1169–77. 10.18632/aging.100408 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Beranger GE, Pisani DF, Castel J, Djedaini M, Battaglia S, Amiaud J, et al. Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology (2014) 155:1340–52. 10.1210/en.2013-1688 [DOI] [PubMed] [Google Scholar]
- 19.Lawson EA, Marengi DA, DeSanti RL, Holmes TM, Schoenfeld DA, Tolley CJ. Oxytocin reduces caloric intake in men. Obesity (Silver Spring) (2015) 23:950–6. 10.1002/oby.21069 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Altirriba J, Pataky Z, Golay A, Rohner-Jeanrenaud F. [Oxytocin: metabolic effects and potential use for obesity treatment]. Rev Med Suisse (2015) 11:97–100. [PubMed] [Google Scholar]
- 21.Blevins JE, Thompson BW, Anekonda VT, Ho JM, Graham JL, Roberts ZS, et al. Chronic CNS oxytocin signaling preferentially induces fat loss in high fat diet-fed rats by enhancing satiety responses and increasing lipid utilization. Am J Physiol Regul Integr Comp Physiol (2016) ajpregu 00220 2015. 10.1152/ajpregu.00220.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]